key: cord-0825789-sc4w6627
authors: Rocke, John; Hopkins, Claire; Philpott, Carl; Kumar, Nirmal
title: Is loss of sense of smell a diagnostic marker in COVID‐19: A Systematic Review and Meta‐analysis
date: 2020-08-01
journal: Clin Otolaryngol
DOI: 10.1111/coa.13620
sha: eb015ca4d7a83ac798fb2d443a660195bd2ecee5
doc_id: 825789
cord_uid: sc4w6627

AIMS: 1. To systematically review the currently available evidence investigating the association between olfactory dysfunction (OD) and the novel coronavirus (COVID‐19). 2. To analyse the prevalence of OD in patients who have tested positive on Polymerase Chain Reaction (PCR) for COVID‐19. 2. To perform a meta‐analysis of patients presenting with olfactory dysfunction, during the pandemic, and to investigate the Positive Predictive Value for a COOVID‐19 positive result in this population. 3. To assess if olfactory dysfunction could be used as a diagnostic marker for COVID‐19 positivity and aid public health approaches in tackling the current outbreak. METHODS: We systematically searched MedLine (PubMed), Embase, Health Management Information Consortium (HMIC), Medrxiv, the Cochrane Library, the Cochrane COVID‐19 Study Register, NIHR Dissemination centre, Clinical Evidence, National Health Service Evidence and the National Institute of Clinical Excellence to identify the current published evidence which associates coronaviridae or similar RNA viruses with anosmia. The initial search identified 157 articles. 145 papers were excluded following application of our exclusion criteria. The 12 remaining articles, that presented evidence on the association between COVID‐19 and olfactory dysfunction, were critically analysed. RESULTS: OD has been shown to be the strongest predictor of COVID‐19 positivity when compared to other symptoms in logistic regression analysis. In patients who had tested positive for COVID‐19 there was a prevalence of 62% of OD. In populations of patients who are currently reporting OD there is a positive predictive value of 61% for a positive COVID‐19 result. CONCLUSION: Our review has shown that there is already significant evidence which demonstrates an association between OD and the novel coronavirus – COVID‐19. It is unclear if this finding is unique to this coronavirus as individual viral phenotypes rarely present in such concentrated large numbers. We have demonstrated that OD is comparatively more predictive for COVID‐19 positivity compared to other associated symptoms. We recommend that people who develop OD during the pandemic should be self‐isolate and this guidance should be adopted internationally to prevent transmission.

There was already a wealth of anecdotal evidence that suggested olfactory dysfunction(OD)was animportant symptom in patients who had contracted the novel SARS-CoV-2 coronavirus (COVID- 19) prior to the main outbreak in the United Kingdom. Initial reports made in newspapers from Germany indicated that as many as two thirds of cases of COVID-19 reported loss of smellwhilst in South Korea,15.3% of patients who have tested positive had perceived disturbance of smell or taste (1) . Since these initial reports a number of studies have demonstrated a clear association between OD and COVID- 19 . This is the first worldwide pandemic where reporting of symptoms, aided by social media and telecommunication systems, has been shared so widely. High profile public figures have reported both symptoms which has led to widespread interest in the symptoms across both the press and the public (2) .

It has previously been demonstrated that the geneticallysimilar SARS-CoVvirus can spread via a synapseconnected route to the medullary cardiorespiratory centre (3) .Coronaviral RNA has been identified post mortem concentrated in the brain-stem of human patients during the previous SARS-CoV pandemic, and studies in mice have shown that previously described corona viruses can invade intracranially when administered intranasally indicating that the virus may travel via the olfactory nerves.Helms et al present a series of patients infected during the current COVID-19 outbreak and demonstrate numerous neurological sequelae and abnormalities on cross-sectional imaging of the brain(4).

Brann et al (in a paper made available prior to peer review) have identified non-neuronal cell types, such as sustentacular and olfactory stem cells as well as horizontal basal cells are the potential target of COVID-19 in the human olfactory epithelium via the ACE2 receptor and the spike protein protease TMPRSS2. This presents three main theories for potential loss of smell in COVID-19. Firstly, a local inflammatory response affecting sensory function, secondly damage to supporting cells and finally Accepted Article escalating damage to the architectural structure of the entire olfactory epithelium, due to damage to sustentacular cells and Bowman's glands (5) . Viral upper respiratory tract infection (URTI) is one of the known major identifiable causes of olfactory dysfunction (OD) due to the degeneration of olfactory epithelium (6) .Due to the widespread and insidious nature of viral URTI there is no data relating to the incidence of post-viral OD for specific viruses but postviral cases typically account for 11% of all cases of OD in the community(7) with cases presenting to specialist clinics typically representing 20% of cases (8) . This group is often represented as a higher proportion in online surveys and patient fora at around 30%(9)(10). Patients often present to the Otolaryngologist in persistent cases but those that resolve soon after the infective process has subsided are likely rarely reviewed or reported (11) .

BMJ best practice have recently published an update on Coronavirus and the range of symptoms that are associated with this. They quote the anecdotal evidence published by ENT UK(1) and the American Academy of Otolaryngology (12) regarding the link between anosmia and coronavirus. Both these international bodies have recommended self-isolation for patients who develop these symptoms(13)Fortunately following lobbying by ENT UK and the British Rhinological Society(BRS)OD has now been incorporated in to national public health policy with Public Health England (PHE) following the WHO in recognising loss of smell and taste as a key symptom of covid-19 infection (2) .

The aim of this systematic review and metanalysis is to identify the currently available evidence for the relationship between COVID-19 and self-reported loss of smell. This will include assessing the potential for OD as a diagnostic marker in COVID-19, outlining the current peer-reviewed evidence relating to this relationship and how it can be utilised going forwards in clinical practice.

We decided to focus on OD and not include loss of taste in this review. OD will lead to reduced retronasal olfaction and subsequently impact the perception of taste in these patients. Flavour perception involves input from ortho and retronasal olfaction and gustation, complemented by trigeminal stimulation through touch and pain fibres. Patients typically find it difficult to isolate true gustatory sensations from retronasal olfaction without objective gustatory testing (14) . Given the difficulties in interpreting this symptom, in the absence of more detailed questions regarding taste perception, we decided to solely review OD.

We The final search was undertaken in 18 th April 2020. We included all years and all languages in the search.

The initial search identified 157 articles. 145 articles were excluded as they did not investigate a link between the current coronavirus outbreak and OD, were conference abstracts, isolated case reports or did not have an English version available. The literature search is presented in the Prisma flow diagram ( Figure 1 ). One case series presented loss of smell and taste in combination, where patients were included if they had experienced either symptom. As such we were unable to isolate olfactory dysfunction in their population. Reporting related but independent symptoms in this way prevents formal analysis of their individual epidemiological factors and impact on patient outcomes.

We used the ROBINS-E (Risk of Bias in Non-randomised Studies -of Exposures) tool to assess the studies for bias. The articles were assessed across 7 parameters; confounding factors, selection of participants, classification of exposures, departures from intended exposures, missing data, measurement of outcomes and the reported result. All the studies were assessed at "serious" risk of bias due these common themes; lack of adjustment for confounding variables, differences in follow up and the start of exposure, variation in reporting, and numerous different subgroups reported.

There were 12articlesthat have investigated the association between COVID-19 and OD. The studies vary in their methodology and in the patient populations that they target. A summary of the studies evaluated, their study methodology and the quality of the evidence is presented below in Table 1 . Several of the studies had not completed the peer review process and this status is also demonstrated in the table. Table 1 2. Description of studies

The most common methodology for assessment in the articles searched was a cross-sectional questionnaire which were conducted over a variety of mediums i.e. face to face, mobile applicationor web-based forms.The cohort of patients targeted also varied between inpatient and outpatient populations and in their geographical location (Tables 2 and 3 ). Whilst there are clear limitations to this approach and it is not possible to demonstrate a direct causal relationship between COVID-19 and ODbut they are able to present associations in the symptomatology of this pandemic.

This article is protected by copyright. All rights reserved

The majority of the remaining studies present case series. They present similar cross-sectional evidence to the questionnaire designed studies with a common aim of investigating the symptomatology of anosmia in the COVID-19 era. This approach should contribute to limiting the level of bias in their results when compared to an outcome-based case series but they are similarly only able to demonstrate association and not causal effect. The complementary data output, between the questionnaire and caseseries approaches, allows us to compare the two approaches concurrently in a meta-analysis.

Walker 

In the only study so far to institute validated quantitative olfactory testing stimuli, within the COVID-19 group. There were no differences in demographics between the two groups but the way the control group was matched will have affected this data (16) .

When analysing data related to COVID-19 positivity it is important to recognise the sensitivity of the test is variable. Bronchoalveolar lavage is the most sensitive test (93%) whilst nasal swabs (63%) and

pharyngeal swabs (46%) have lower positive rates 14 (16, 17) . Due to the relatively low sensitivity of the test used Accepted Article there will be a proportion of false negatives that will falsely lower the incidence of COVID-19 positivity in the OD groups and will therefore also impact on the calculation of sensitivity and specificity.

The majority of the responses to questionnaires were received remotely using electronic response forms of mobile based applications which will cause selection bias. Younger more technologically interactive cohort are more likely to interact and this sub-group seem to be less affected by COVID-19 when compared to older age groups who have a higher morbidity and mortality (18) . For example, Menni et al, who used a mobile based application, report an average age of 41.48 (CI = 13.77) for those in their non-PCR-tested group, including over 1.5million people (19) . Hospitalised populations are also less likely to interact with these methods due to their disease severity, internet connection or associated interventional treatments.

Cross-sectional questionnaires and case series are prone to bias due to influence of confounding variables, assessment of patients at different time points relative to their exposure and reporting bias. In case series specifically consecutive patients often missed in data collection. In these studies, however the researchers are simply presenting patient factors and associated symptoms rather than treatments or interventions and their subsequent effects or outcomes and this observational nature could help to reduce observer bias. In studies that were conducted requiring historical data from the patients there is a risk of recall bias and under-reporting or inaccuracies of symptoms specifically where onset and duration of symptoms is involved.

Two distinct populations havebeen assessedin the literature. The first groupwere those patients who had received testing and were confirmed positive COVID-19 patients, the prevalence of OD was then analysed. The second were people who had experienced OD and the prevalence of COVID-19 within this cohort. Menni et aland Yan et alreport data from both groups concurrently and presented data for both populations in their results (19, 20) . "diagnostic criteria" that is not described they divided their patients in to severe and non-severe groups.

Of the 11 patients who had reported hyposmia 3 were non-severe and 8 were severe (17) .

Giacomelli et al interviewed 59 of 88 inpatients with COVID-19 demonstrated on PCR, there were 29 nonrespondents due to receiving ventilation, dementia and linguistic barriers. They report combined rates of smell or taste disturbance and as such comparative incidence rates solely for OD was not possible to produce from the data presented. In their cohort the olfactory and gustatory disorders occurred in proportionally younger and more commonly female subjects and no patients had recovered at the time of interview. No data relating to time of interview following onset of symptoms is reported (22) .

In the studies that investigated olfactory symptoms independently we present the prevalence rates in Table 2 to form a meta-analysis for the prevalence of OD in the population of patients that have tested positive.

Accepted Article This article is protected by copyright. All rights reserved

Due to the differences in public health approaches and the availability of testing it is difficult to Table 3 demonstrates the average ages and gender proportions of the six studies with ODcohorts. Table 3 Discussion

Our review has shown that there is already significant evidence which demonstrates an association between OD and the novel coronavirus -COVID-19. It is unclear if this finding is unique to this coronavirus as individual viral phenotypes rarely present in such concentrated large numbers. Classically patients present with persistent symptoms following a viral illness many weeks or months after. The

symptomatology during the infective phase of the virus has not previously been studied and therefore it is not possible to draw direct comparison between other similar viruses. Walker et al have however demonstrated trends between increasing cases of COVID-19 and the increase in positive novel coronavirus cases that was not mirrored during the previous H1N1 pandemic in 2009(15) .

Due to the rapid spread of COVID-19 in this pandemic it is understandable that there is a lack of studies using objective measures and rigorous controls. The most common methodologies used were crosssectional questionnaires and case series. These approaches are at risk of bias and we can only discuss associations as a result. Further research will be required to demonstrate clearer links between OD and COVID-19 going forwards.

When we assessedpatients who had experienced OD during the outbreak there were several studies that demonstrated an increase in the prevalence of loss of smell in their populations when compared to previous estimates (19, 24, 25) . The largest data sets, conducted predominantly in the outpatient setting, by Hopkins and Bagheri et al indicated a female preponderance in their cohorts (73% and 71% respectively). These two studies also demonstrated an average affected age between 30-40. It has been demonstrated that both advanced age and the male sex are risk factors for the severe form of the disease and an increased rate of mortality (18) . It could be that this cohort of patients were not targeted by this study due to the more elderly populations not interacting with web-based surveys or being within the inpatient population due to their disease severity. Moein et al demonstrated in their study of inpatients that OD was a common finding in this population too when they applied objective UPSIT testing to confirmed cases (16) . Further research is needed to identify if the incidence of ODvaries between different ages and genders and as such if particular disease phenotypes for COVID-19 can give clinicians prognostic information.

In areas where testing has not been adopted widely tracking of this ODcould be vital in identifying hotspots where population-based management strategies can then be targeted. Tracking OD using mobilebased applications, such as the one developed by Menni et al, will allow real time data tracking for aid models in the prediction of national or regional COVID-19 cases (19) . This approach could lead to specific social distancing measures being implemented in areas where OD is wide-spread and will also help in modelling when these measures could be relaxed as most patients seem to recover their sense of smell following the illness.

Our meta-analysis has demonstrated that the prevalence of OD in patients who have a positive PCR test for COVID-19 is 62%. OD was demonstrated to be the most strongly associated symptom, for a positive test, when compared to fever, cough, fatigue, dyspnoea and diarrhoea (19, 20) . In people who reported

OD and had received PCR swab there was a positive predictive value of 61% for a positive result. The evidence to support an association between OD and COVID-19 continues to grow. The symptom has now been recognised by the World Health Organisation and Public Health England (29) . This change in approach should mean an increase in the number of positive COVID-19 cases self-isolating and a subsequent reduction in the chance of spread with benefits for public health and containment of the pandemic.

The authors declare that they have no relevant or material financial interests that relate to the research described in this paper.

The data that support the findings of this study are available from the corresponding author upon reasonable request. 

This article is protected by copyright. All rights reserved 

This article is protected by copyright. All rights reserved 

Loss of Sense of Smell as a marker of COVID-19

Why are loss of smell and taste reportedly symptoms of COVID-19? The Independent

The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients

Neurologic Features in Severe SARS-CoV-2 Infection

Non-neuronal expression of SARS-CoV-2 entry genes in the olfactory system suggests mechanisms underlying COVID-19 associated anosmia. 2020. *Pre-print, awaiting peer-review PPR130125

Olfactory epithelium: Cells, clinical disorders, and insights from an adult stem cell niche

Olfactory dysfunctions. Epidemiology and therapy in Germany, Austria and Switzerland

Smell and Taste Disorders in the UK: First experiences with a specialised smell and taste outpatient clinic

Hidden consequences of olfactory dysfunction: a patient report series

Validation of the olfactory disorders questionnaire for English-speaking patients with olfactory disorders

Clinical practice guidelines for the management of olfactory dysfunction -Secondary publication

Hyposmia, and Dysguesia Symptoms of Coronavirus Disease. AAO-HNS 2020

Investigation of the role of major respiratory viruses in the aetiology of nasal polyps using polymerase chain reaction technique

Retronasal perception of odors

The use of google trends to investigate the loss of smell related searches during COVID-19 outbreak

Smell dysfunction: a biomarker for COVID-19

Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease

Estimation of Risk Factors for COVID-19 mortality -preliminary results. 2020.*Pre-print, awaiting peer-review PPR114369

Association of chemosensory dysfunction and Covid-19 in patients presenting with influenza-like symptoms

Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study

Self-reported olfactory and taste disorders in SARS-CoV-2 patients: a cross-sectional study

COVID-19 Anosmia Reporting Tool: Initial Findings

Coincidence of COVID-19 epidemic and olfactory dysfunction outbreak

Presentation of new onset anosmia during the COVID-19 pandemic

Isolated sudden onset anosmia in COVID-19 infection. A novel syndrome? Rhinology

Sinonasal pathophysiology of SARS CoV-2 and COVID-19: A systematic review of the current evidence

Statement from the UK Cheif Medical Officers on an

This article is protected by copyright. All